Amur Minerals (CRTX) AI Stock Analysis

• Market Cap: £6.21M
• Dividend Yield: N/A
• Average Volume (3M): 84.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 51,735,268
• 10 Day Avg. Volume: 114,469
• 30 Day Avg. Volume: 84,037
• PEG Ratio: -0.03
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 33.47
• P/FCF Ratio: -0.87
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: 12.50 p ▲(25.00% Upside)
• Action: Reiterated Date: 02/03/26
• Date: Action: Reiterated 02/03/26

The score is held back primarily by weak financial fundamentals (very small revenue with ongoing losses and negative free cash flow), despite improved loss/cash-burn trends and a debt-free balance sheet. Technically, momentum is positive, but the very high RSI suggests near-term overextension. Valuation remains unattractive/unclear due to negative earnings and no indicated dividend support.

Positive Factors

Conservative leverage

A debt-free 2024 balance sheet materially reduces fixed financing obligations and default risk, preserving strategic optionality. For a loss-making company, low leverage lengthens time to next financing and lowers cash interest burden, a durable reduction in financial vulnerability.

Improving loss and cash-burn trends

Meaningful year‑over‑year improvement in net loss and reduced cash burn signals management execution on cost control and operational efficiency. Sustained tightening of cash outflows improves runway and reduces near‑term reliance on capital markets, a structurally positive trend.

High gross margin potential

An 84% gross margin indicates attractive unit economics if revenue scales, implying high operating leverage potential. Structurally, strong gross margins support profitability upside once fixed costs are absorbed, enhancing long‑term viability despite current low sales.

Negative Factors

Very small revenue and negative free cash flow

Extremely low sales combined with persistent negative operating and free cash flow demonstrate the business is not self‑funding. Over time this forces recurring external financing, increases dilution risk, and limits the firm's ability to invest in R&D or commercial scale‑up.

Eroding capital base and negative returns

A sharply weakened balance sheet and a roughly -41% ROE reflect cumulative losses eroding shareholder capital. This structural deterioration reduces financial resilience, constrains the ability to fund growth internally, and raises the probability of dilutive capital raises.

Very limited operational scale

A headcount of four implies constrained internal capacity to execute complex biotech development or commercialization programs. Reliance on external partners or contractors increases execution risk, slows scaling, and can raise long‑term costs and coordination challenges.

Amur Minerals Business Overview & Revenue Model

Company Description

CRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin following the removal of a tumor, ensuring effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. Its ChemoSeed used for treatment of gliomas, a brain tumor. The company was founded in 2016 and is based in Road Town, the British Virgin Islands.

How the Company Makes Money

null

Amur Minerals Financial Statement Overview

Summary

Results show meaningful improvement year over year (smaller net loss and reduced cash burn in 2024), and the balance sheet has no debt. However, revenue remains minimal, profitability is still negative, free cash flow is persistently negative, and the equity base has shrunk—indicating ongoing dependence on external funding or a step-change in operations.

Income Statement

The company has minimal revenue (2024: 25k vs. 2023: 57k) and continues to run significant operating losses, though losses improved meaningfully in 2024 (net loss -607k vs. -9.65M in 2023; EBIT loss -582k vs. -2.26M). Reported gross margin in 2024 is high (84%), but the revenue base is extremely small, so profitability remains dominated by operating costs. Overall, the trajectory improved in 2024, but earnings quality is weak due to persistent losses and limited scale.

Balance Sheet

Leverage looks conservative in 2024 with no total debt and positive equity (1.48M), which reduces financial risk. However, the balance sheet has weakened sharply over time, with equity and assets falling substantially from 2021–2022 levels, and returns on equity remain negative (2024 ROE about -41%). In short: low leverage is a strength, but ongoing losses and a shrinking capital base are key concerns.

Cash Flow

Cash generation is a clear weakness: operating cash flow and free cash flow are negative across all periods shown (2024 operating cash flow -933k; free cash flow -961k). Cash burn improved versus 2023 (operating cash flow -2.77M; free cash flow -2.77M), but the business is still not self-funding. Free cash flow tracking close to net income indicates losses are translating into real cash outflows rather than being offset by non-cash items.

Breakdown	TTM	Dec 2024	Dec 2023	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	0.00	25.00K	57.37K	0.00	0.00	0.00
Gross Profit	-4.12K	21.00K	16.57K	0.00	0.00	-3.90K
EBITDA	-1.24M	-566.00K	-2.26M	-1.81M	-1.30M	-3.08M
Net Income	-1.28M	-607.00K	-9.65M	-2.45M	-1.54M	-2.08M
Balance Sheet
Total Assets	2.38M	1.82M	4.79M	23.89M	23.06M	23.71M
Cash, Cash Equivalents and Short-Term Investments	479.03K	1.28M	4.38M	2.90M	4.93M	2.79M
Total Debt	0.00	0.00	888.54K	0.00	0.00	0.00
Total Liabilities	583.34K	341.00K	662.00K	765.65K	832.07K	771.06K
Stockholders Equity	1.80M	1.48M	4.12M	23.13M	30.11M	31.35M
Cash Flow
Free Cash Flow	-1.19M	-961.00K	-2.77M	-2.99M	-1.40M	-2.12M
Operating Cash Flow	-1.19M	-933.00K	-2.77M	-2.73M	-1.10M	-1.68M
Investing Cash Flow	-91.96K	2.33M	34.93M	-511.00K	6.04M	-5.18M
Financing Cash Flow	0.00	-67.00K	-31.45M	968.00K	0.00	9.89M

Amur Minerals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CRTX	47 Neutral	£6.21M	-1.04	-78.00%	―	―	―
ROQ	44 Neutral	£1.68M	-0.94	-18.71%	―	―	―
CIZ	43 Neutral	£6.14M	-4,173.96	-433.59%	―	―	―
NFX	42 Neutral	£4.11M	-5.98	-153.80%	―	―	-616.67%

Amur Minerals Corporate Events

CRISM Wins FDA Orphan Drug Status for Glioma ChemoSeed Programme

CRISM Therapeutics has secured Orphan Drug Designation from the U.S. FDA for irinotecan to treat malignant glioma, expanding beyond glioblastoma to cover all high-grade gliomas and marking a key regulatory and commercial milestone for its irinotecan-ChemoSeed programme. Coupled with the UK MHRA’s Innovation Passport under ILAP, the designation is expected to strengthen CRISM’s strategic position, support its Phase 2 registration-grade trial in surgically resectable glioblastoma, and potentially facilitate accelerated, coordinated regulatory review and commercialisation across major global oncology markets.

The most recent analyst rating on (GB:CRTX) stock is a Hold with a £12.50 price target. To see the full list of analyst forecasts on Amur Minerals stock, see the GB:CRTX Stock Forecast page.

CRISM Therapeutics Wins Key Japanese Patent for ChemoSeed Cancer Implant

CRISM Therapeutics has secured a Japanese patent for its lead product ChemoSeed, covering both the manufacturing processes and therapeutic use of irinotecan-based biodegradable chemotherapeutic implants, particularly for treating brain tumours such as glioblastoma. Management describes Japan as a key market and sees the patent as strengthening the company’s intellectual property portfolio and appeal to potential commercial partners, reinforcing its positioning ahead of a planned registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in surgically resectable glioblastoma patients in early 2026.

The most recent analyst rating on (GB:CRTX) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Amur Minerals stock, see the GB:CRTX Stock Forecast page.

CRISM Therapeutics Reveals Updated Major Shareholders After December Fundraising

CRISM Therapeutics has published the results of an independent analysis of its shareholder register as at 31 December 2025, identifying five significant shareholders each holding at least 3% of its ordinary share capital, with CEO Andrew Webb the largest shareholder at 14.1%. The company also disclosed that, following its recent placing and retail offer completed in December 2025, former major shareholders Linista Group Inc. and Spreadex no longer hold disclosable stakes, signalling a reshaped investor base as CRISM advances its clinical development plans.

The most recent analyst rating on (GB:CRTX) stock is a Hold with a £9.50 price target. To see the full list of analyst forecasts on Amur Minerals stock, see the GB:CRTX Stock Forecast page.